A single fecal microbiota transplantation from healthy donors increases the efficacy of immune checkpoint inhibition in both NSCLC and melanoma.

The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...

Patients should be selected for treatment based on the presence of an NRG1 gene fusion in tumor specimens. The Food and Drug Administration (FDA) has granted accelerated approval to Bizengri ® ...

A retrospective study finds that more than one third of patients with stage I-IIIA non-small cell lung cancer do not undergo ...

Ocean Biomedical has announced promising research findings on its cancer immunotherapy candidates, which can enhance the effectiveness of tyrosine kinase inhibitors (TKIs) like osimertinib for ...

Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node ...

Summit Therapeutics' ivonescimab BLA wins FDA acceptance for EGFR-mutated NSCLC, with a PDUFA action date of Nov. 14, 2026.

In this study, researchers evaluated patients who had incomplete cCRT or experienced progression during or within 42 days of receiving cCRT, with an aim of identifying risk factors for these outcomes.

About 80% of people who have lung cancer have non-small-cell lung cancer. NSCLC usually spreads more slowly than small-cell lung cancers. Both cancers affect the lungs and have similar symptoms, but ...